Immunovant (IMVT)
(Delayed Data from NSDQ)
$30.40 USD
+0.47 (1.57%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $30.38 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
IMVT 30.40 +0.47(1.57%)
Will IMVT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for IMVT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMVT
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
IMVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?
Other News for IMVT
JPMorgan SMid cap biotech analyst holds an analyst/industry conference call
JPMorgan SMid cap biotech analyst holds an analyst/industry conference call
Noteworthy Friday Option Activity: IMVT, ALB, GCT
Nike upgraded, PayPal downgraded: Wall Street's top analyst calls
Immunovant resumed with an Outperform at Raymond James